JP2004525917A - ヘパリンコファクターｉｉアゴニストと血小板ｉｉｂ／ｉｉｉａ受容体アンタゴニストとの組み合わせ、およびその使用 - Google Patents

ヘパリンコファクターｉｉアゴニストと血小板ｉｉｂ／ｉｉｉａ受容体アンタゴニストとの組み合わせ、およびその使用 Download PDF

Info

Publication number
JP2004525917A
JP2004525917A JP2002571091A JP2002571091A JP2004525917A JP 2004525917 A JP2004525917 A JP 2004525917A JP 2002571091 A JP2002571091 A JP 2002571091A JP 2002571091 A JP2002571091 A JP 2002571091A JP 2004525917 A JP2004525917 A JP 2004525917A
Authority
JP
Japan
Prior art keywords
agonist
platelet
iiia receptor
receptor antagonist
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002571091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525917A5 (https=
Inventor
ディー カーディン，アラン
ゴープ，コーニーリアス エル ヴァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IntimaX Corp
Original Assignee
IntimaX Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IntimaX Corp filed Critical IntimaX Corp
Publication of JP2004525917A publication Critical patent/JP2004525917A/ja
Publication of JP2004525917A5 publication Critical patent/JP2004525917A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002571091A 2001-03-09 2002-03-07 ヘパリンコファクターｉｉアゴニストと血小板ｉｉｂ／ｉｉｉａ受容体アンタゴニストとの組み合わせ、およびその使用 Pending JP2004525917A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/802,775 US6518244B2 (en) 2000-03-09 2001-03-09 Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
PCT/US2002/006969 WO2002072132A1 (en) 2001-03-09 2002-03-07 Combinations of heparin cofactor ii agonist and platelet iib/iiia antagonist, and uses thereof

Publications (2)

Publication Number Publication Date
JP2004525917A true JP2004525917A (ja) 2004-08-26
JP2004525917A5 JP2004525917A5 (https=) 2006-01-05

Family

ID=25184646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002571091A Pending JP2004525917A (ja) 2001-03-09 2002-03-07 ヘパリンコファクターｉｉアゴニストと血小板ｉｉｂ／ｉｉｉａ受容体アンタゴニストとの組み合わせ、およびその使用

Country Status (5)

Country Link
US (1) US6518244B2 (https=)
EP (1) EP1377309A1 (https=)
JP (1) JP2004525917A (https=)
CA (1) CA2440557C (https=)
WO (1) WO2002072132A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505538A (ja) * 2016-02-17 2019-02-28 エント テクノロジーズ ピーティーワイ リミテッド 副鼻腔疾患および障害の治療のための組成物と方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135315A1 (de) * 2001-07-19 2003-01-30 Bayer Ag Stents
US6908907B2 (en) * 2002-04-22 2005-06-21 El-Naggar Mawaheb M. Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
US7132398B2 (en) * 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
AU2005229015C1 (en) 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
NL2000126C2 (nl) * 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.
US8986713B2 (en) * 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
ES2955183T3 (es) 2011-03-11 2023-11-29 Gore & Ass Mejoras para las entidades biológicas inmovilizadas
EP3731870B1 (en) 2017-12-26 2025-11-12 Liqmeds Limited Liquid oral formulations for pde v inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3124384C2 (de) 1981-06-22 1985-05-15 Herbert Prof. Dr. 1000 Berlin Voß Dermatanpolysulfat, Verfahren zu dessen Herstellung und dieses enthaltendes virushemmendes Mittel
FR2584728B1 (fr) 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5686566A (en) 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregation inhibitors
CA2000650A1 (en) 1989-10-13 1991-04-13 Louis Jaques Product and process for the treatment and prevention of intravascular thrombi and atherosclerosis
US6008193A (en) 1990-03-02 1999-12-28 Bio-Technology General Corp. Methods of using human von Willebrand factor GPIb binding domain polypeptides
DK0527798T3 (da) 1990-04-06 1997-12-15 Jolla Cancer Res Found Fremgangsmåde og sammensætning til behandling af thrombose
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
EP0557406A4 (en) 1990-11-01 1993-10-06 Smith-Kline Beecham Corporation -g(g)-turn peptidomimetics as fibrinogen antagonists
WO1992019595A1 (en) 1991-05-07 1992-11-12 Merck & Co., Inc. Fibrinogen receptor antagonists
IT1251182B (it) 1991-08-28 1995-05-04 Opocrin Spa Oligosaccaridi di dermatan solfato, processo per la loro produzione e relative composizioni farmaceutiche.
IT1251183B (it) 1991-08-28 1995-05-04 Opocrin Spa Dermatan solfato ad alto titolo, dotato di elevata attivita' trombolitica, e forme farmaceutiche che lo contengono.
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
JP2855307B2 (ja) 1992-02-05 1999-02-10 生化学工業株式会社 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法
US5227490A (en) 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
US5312923A (en) 1992-02-28 1994-05-17 Merck & Co., Inc. Process for preparing fibrinogen receptor antagonists
WO1994009034A1 (en) 1992-10-12 1994-04-28 Agen Limited Clot directed anticoagulant, process for making same and methods of use
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
US5731324A (en) 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5972967A (en) 1996-10-23 1999-10-26 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
KR100240544B1 (ko) 1995-12-20 2000-01-15 고바야시 유끼오 혈관 내막 비후 억제제
US5952306A (en) 1996-01-16 1999-09-14 Merck & Co., Inc. Integrin receptor antagonists
WO1997035592A1 (en) 1996-03-28 1997-10-02 G.D. Searle & Co. Iib/iiia antagonists co-administered with aspirin and/or heparin
US5922690A (en) * 1996-04-25 1999-07-13 Van Gorp; Cornelius L. Dermatan disulfate, an inhibitor of thrombin generation and activation
JP2002501936A (ja) 1998-02-02 2002-01-22 メルク エンド カムパニー インコーポレーテッド 低分子量ヘパリンをＧＰＩＩｂ／ＩＩＩａ拮抗物質と組合わせて使用する血小板凝集の抑制

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505538A (ja) * 2016-02-17 2019-02-28 エント テクノロジーズ ピーティーワイ リミテッド 副鼻腔疾患および障害の治療のための組成物と方法

Also Published As

Publication number Publication date
EP1377309A1 (en) 2004-01-07
CA2440557A1 (en) 2002-09-19
US20010036932A1 (en) 2001-11-01
WO2002072132A1 (en) 2002-09-19
US6518244B2 (en) 2003-02-11
CA2440557C (en) 2011-04-19

Similar Documents

Publication Publication Date Title
JP2004525917A (ja) ヘパリンコファクターｉｉアゴニストと血小板ｉｉｂ／ｉｉｉａ受容体アンタゴニストとの組み合わせ、およびその使用
JP5554756B2 (ja) カリクレインインヒビターおよびその使用
RU2166326C2 (ru) Комбинация тромболитически активных белков и антикоагулянтов
EP1392329B1 (en) Use of sulodexide for the treatment of inflammatory bowel disease
Escolar et al. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions
US9539218B2 (en) Prevention and treatment of thromboembolic disorders
CN101384259A (zh) 作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂
WO1997035579A1 (en) A method for inhibiting clot formation
AU766089B2 (en) Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA), a GPIIb/IIIa antagonist, low molecular weight heparin or heparin
AU740941B2 (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6136794A (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
Sorbera et al. Melagatran and ximelagatran
JP2008007512A (ja) 動脈狭窄の減弱方法
JPH06228006A (ja) トロンビン阻害剤の眼フィブリン形成阻害のための使用
AU2002248566A1 (en) Combinations of heparin cofactor II agonist and platelet IIB/IIIA antagonist, and uses thereof
JP2004503509A (ja) メラガトラン及びＶＩＩａ因子阻害剤を含んでなる組合せ製品
Cannon et al. Clotting for the clinician: an overview of thrombosis and antithrombotic therapy
McGregor Current perspective on antithrombin drugs
Wildes et al. Essential drugs in anesthetic practice
MXPA01009080A (en) Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050418

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20070330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080910

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090210